Illumina is working on a series of oncology partnerships that aim to expand the reach of its comprehensive genomic profiling family of products, TruSight Oncology.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
